The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Glioma
- Focus Adverse reactions
- Acronyms Toca7
- Sponsors Tocagen
- 09 Aug 2017 According to a Tocagen media release, the company is planning to start this trial in the first half of 2018.
- 30 Sep 2016 According to a Tocagen media release, the company will present the data from this study at the 10th International Oncolytic Virus Meeting.
- 10 Nov 2015 New trial record